Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial

Participants and study design

Phase IIb was designed as a multicenter, adaptive, parallel, double blind, randomized, placebo controlled trial for evaluating the immunogenicity, safety and reactogenicity of two doses of SOBERANA 02 and the heterologous scheme with a third dose with SOBERANA Plus. Healthy adults aged 19-80 years, of both sexes were recruited through public advertisement at community or professional environment close to the clinical site. Detailed information about all eligibility criteria are summarized in the Supplementary Material Appendix Section A.

Participants were randomly assigned at a 4:4:1 ratio to receive one of the two API batches of SOBERANA 02 or placebo (810 subjects; API 1: 354, API 2: 354 and 102 in the placebo group). Randomization was stratified in four 10-years age subgroups (from 19-29, 30-39, 40-49, 50-59 years), and one 21-years age subgroup (60-80 years).

The trial was conducted at two clinical sites: Clinic #1 at “La Lisa” Municipality and Polyclinic “19 de Abril” at “Plaza de la Revolución” Municipality, Havana, Cuba. (Cuban Public Registry of Clinical Trials, included in WHO International Clinical Registry Trials Platform: https://rpcec.sld.cu/trials/RPCEC00000347 [7].)

Products under evaluation

SOBERANA 02 (FINLAY-FR-2) and SOBERANA Plus (FINLAY-FR-1A) are vaccine candidates based on the recombinant receptor binding domain (RBD) of SARS-CoV-2 virus produced in CHO cells. The RBD sequence selected, Arg319-Phe541-(His)₆, includes free Cys538. This residue provides a suitable conjugation site to tetanus toxoid (in SOBERANA 02) [4]; it also allows dimerization through a disulphide bridge linking two RBD molecules (in SOBERANA Plus) [3]. Vaccines and placebo were produced under Good Manufacturing Practice at Finlay Vaccine Institute and the Center of Molecular Immunology in Havana, Cuba. SOBERANA 02 active pharmaceutical ingredient (API) batches resulted in three batches of the final product: EC-CVRBDC-2003 and EC-CVRBDC-2004 (containing API 1), and EC-CVRBDC-2005 (containing API 2); SOBERANA Plus batches were EC-CVRBDd-2008 and EC-CVRBDd-2101; placebo batch was: E1001PS02. Vaccines composition has been described previously [6]; the placebo contained the excipients of SOBERANA 02. Vaccine and placebo formulations were visually undistinguishable.

Ethical considerations

The phase II clinical trial protocol was reviewed and approved by an ad hoc centralized Research Ethics Committee from the Medical Sciences University, Faculty of Medicine “Manuel Fajardo”, Havana, designed by the Health Innovation Committee from the Cuban Ministry of Health (MINSAP). The Cuban National Regulatory Agency (Center for State Control of Medicines and Medical Devices, CECMED) approved the trial and the procedures (CECMED, Authorization date: 17^th December 2020, reference number: 05.019.20BA).

The National Clinical Trials Coordinating Center (CENCEC) was responsible for monitoring the trial in terms of adherence to the protocol and Good Clinical Practice as well as data accuracy. An Independent Data Monitoring Committee (conformed by six external and independent members specialized on clinical practice, epidemiology and statistic) supervised the study.

The trial was conducted following the Declaration of Helsinki, Good Clinical Practice and the rules of the Cuban National Immunization Program. During participants recruitment, the investigators provided the potential participants all relevant information (both orally and written) about the vaccine candidates, and the potential risks and benefits of the trial. All questions and doubts were clarified before enrollment. The decision to participate in the study was voluntary and not remunerated. Written informed consent was obtained from all participants.

Procedures

Participants received intramuscular injections in the deltoid region, 28 days apart. They were closely followed for one hour after each injection for safety evaluation. Medical visits were planned at 24, 48 and 72 hours, 14 and 28 days after each dose. Any adverse event was self-registered by the participants on a diary card and recorder during medical visits.

Serum samples were collected on days 0 (baseline) and 56 from all subjects; on days 14 and 70, blood samples were taken from 50% of the participants while samples from the other 50% were collected on days 42 and 84. To evaluate the duration of the humoral response, seven to eight months after completing the vaccination schedule, and after signing a new informed consent, another serum sample was obtained from a subset of vaccinated participants.

Outcomes

The primary outcomes were percentage of subjects with seroconversion ≥4-fold the anti-RBD IgG pre-vaccination level. Secondary outcomes included: 1) Serious Adverse Events (AEs) measured daily for 28 days after each dose; 2) Solicited Local and Systemic AEs for 7 days after each dose; 3) Unsolicited AEs measured daily for 28 days after each dose; 4) Conventional neutralizing antibody titers (cVNT₅₀) of a subset of samples from seroconverted subjects and 5) Inhibition of RBD-hACE2 interaction expressed as % and molecular inhibitory titer (mVNT₅₀). Outcomes are detailed in Supplementary Material, Appendix A-2).

Immune response assessment

All immunological evaluations were performed by external laboratories on blind samples. Anti-RBD IgG response and molecular- and conventional-virus neutralization titers were evaluated as described [6] (See Supplementary Materials Appendix C).

Anti-RBD IgG concentration, inhibition of RBD-hACE2 interaction and mVNT₅₀ were determined on days 0, 14, 42, 56, 70, 84. Conventional neutralizing antibody titers (cVNT₅₀) against D614G variant was evaluated in a subset of samples randomly selected from the individuals with seroconversion on days 0, 56, 70 and 84. cVNT₅₀ against VOC was also determined in a subset of samples with cVNT₅₀ vs. D614G >20. Molecular neutralization assay (% Inhibition RBD:hACE2) was determined at T0 only if the sample has pre-vaccination IgG concentration over 7.8 AU/ml (4-fold the limit of quantification in ELISA assay, 1.95 AU/ml). Anti-RBD IgG concentration, and mVNT₅₀ were also determined after 7-8 months of the last dose.

The humoral immune response was compared with that of a Cuban Convalescent Serum Panel (CCSP) made with serum from 68 COVID-19 convalescent patients and characterized with the same techniques used in clinical trials [6,8].

Safety evaluation

Solicited local and systemic AEs were measured daily from days 0 to 7 following each immunization. Other AEs were self-recorded until completion of the 28 days follow-up period. The severity of solicited AEs was graded according to Brighton Collaboration definition and the Common Terminology Criteria for Adverse Events version 5·0. All AEs were reviewed for causality, and classified according to WHO [9].

Statistical analysis

Calculation of sample size was done before starting phase II study (this included phases IIa and IIb) considering a two-sided 95% confidence interval for the difference between two proportions with a width equal to 0.16, to estimate a difference between each API batch and placebo group of around 50%, with a lower bound of the confidence interval greater than 30% and a dropout of 15%. This resulted in a phase II sample size of 910 subjects randomized 4:4:1 in three groups (vaccine API 1, vaccine API 2 and placebo) (404:404:102), and allowing a loss of up to 138 subjects. Stage IIb excluded the 100 participants in phase IIa, giving a sample size of 810 subjects. The evaluation of the study hypothesis remaining valid after excluding stage IIa participants.

Safety and reactogenicity endpoints are described as frequencies (%). Quantitative demographic characteristics are reported as mean, standard deviation (SD), median, interquartile range, and range. We calculated seroconversion rate for anti-RBD IgG antibodies (≥4-fold increase in antibody concentration over baseline) for each subject. Anti-RBD IgG concentration and % of inhibition of RBD-hACE2 interaction were expressed as median and interquartile range; molecular virus neutralization titer (mVNT₅₀) and conventional virus neutralization titer (cVNT₅₀) were expressed as geometric mean (GMT) and 95% confidence intervals (CI). Spearman’s rank correlation was used to assess relationships among techniques used to evaluate the immune response. The Student t-Test or the Wilcoxon Signed-Rank Test were used for before-after statistical comparison. Statistical analyses were done using SPSS version 25.0; EPIDAT version 12.0 and Prism GraphPad version 6·0. An alpha signification level of 0.05 was used.

Flow chart and demographics

From mid-January to end-February 2021, 948 individuals were recruited for phase IIb trial, 138 were excluded and 810 included (Figure 1). Eligible participants were randomly assigned for receiving vaccine (two doses of SOBERANA 02 and one dose of SOBERANA Plus) or placebo, at 28 days intervals.

• Download figure
• Open in new tab

Figure 1.

Flow chart of clinical trial phase IIb

The demographics characteristics are summarized in Table 1. The mean age of participants was 47 years (SD 15.8) predominating white race (73.2%).

Immune response assessment

On day 14, the proportion of subjects with ≥ 4-fold increase in anti-RBD IgG concentration was significantly different (p<0.005) in vaccine (20%) and placebo (3.8%) groups. These values increased to 76.3 % (median 26.5 AU/ml) after second dose (sample on T56) and 96.8% (median 122.2 AU/ml) after third dose (samples collected either on T70 or T84) while values for placebo were 7.3% on T56. This represents a 4.6-fold increase in anti-RBD IgG concentration (p<0.0005) after the third dose compared to the second and a 2.4-fold increase compared to the Cuban Convalescent Serum Panel (CCSP). (Figure 2A, and Supplementary materials Appendix B Table 1).

• Download figure
• Open in new tab

Figure 2.

Immunogenicity after vaccination in subjects aged 19-80 years. A) Kinetics of anti-RBD IgG concentration expressed in arbitrary units/mL (median, 25^th-75^th percentile). B) % inhibition of RBD:hACE2 interaction at 1/100 serum dilution (median, 25th-75th percentile). C) Molecular virus neutralization titer mVNT₅₀, highest serum dilution inhibiting 50% of RBD:hACE2 interaction (GMT, 95% CI). D) Conventional live-virus neutralization titre cVNT₅₀ (GMT, CI 95%) against SARS-CoV-2 D614G variant.

Footnote: Blue dots: response after two doses (on T0, T28) of SOBERANA 02. Green dots: response at T70 or T84 after receiving the third dose on T56, this one of SOBERANA Plus. Brown dots: subjects receiving placebo. CCSP (purple): Cuban Convalescent Serum Panel. p value: statistic differences (on T70 orT84) compared to T56 or T0.

The molecular inhibition of RBD:hACE2 interaction (expressed as % inhibition and molecular virus neutralization titer, mVNT₅₀) also increased. The inhibition median after two doses of SOBERANA 02 was 28.4% (25^th-75^th percentile 10.8; 67.0), similar to the value for CCSP, 32% (25^th-75^th percentile 26.6; 62.2). After the third dose this value increased to 85.5% (25^th-75^th percentile 49.4; 93.1); the GMT for mVNT₅₀ was 289.0 (95% CI: 258.4; 323.4) which represented a 4.6-fold increase compared to the value after the second dose (p<0.0005) and a 6.9-fold increase compared to CCSP value. (Figure 2B-C, Supplementary materials Appendix B Table 1).

The conventional virus neutralization titre (cVNT₅₀) was evaluated in a subset of samples randomly selected from participants with seroconversion after second (on T56) and third doses (on days T70 or T84). After two doses, the cVNT₅₀ GMT was 65.9 (95% CI 46.9; 92.7), comparable to the CCSP value (GMT 41.8; 95% CI 27.7; 63.2). After the third heterologous dose a remarkable, statistically significant increase (p<0.0005) was observed, attaining a GMT of 219.6 (95% CI 179.5; 268.8); this is 3.3-fold the value after the second dose and 4.7-fold the value of CCSP (Figure 2D, Supplementary materials Appendix B Table 1).

Neutralization against SARS-CoV-2 variants was also analyzed in sera from 18 subjects that completed the vaccination schedule. As seen in Figure 3, cVNT₅₀ GMT was 364 (95% CI 304.7; 434.8) against D614G variant, whereas cVNT₅₀ GMT of 339 (95% CI 277.3; 414.4), 156.7 (95% CI 122.4; 200.6) and 51.4 (95% CI 31.23; 84.49) were obtained against alpha, delta and beta variants, respectively. Compared to D614G, no differences were detected in neutralizing titres against alpha variant: however, there was a reduction of 2.32-fold and 7-fold against delta and beta variants, respectively. All analysed sera conserved neutralizing activity against alpha and delta variants, and a 94% of sera conserved activity against beta variant.

• Download figure
• Open in new tab

Figure 3.

Live-virus neutralization titer against SARS-CoV-2 variants. Sera from 18 subjects vaccinated with complete schedule (two doses SOBERANA 02 + one dose SOBERANA Plus, 28 days apart) were evaluated (cVNT₅₀: GMT, 95% CI) against variants B.1.1.7 alpha, B.1.617.2 delta, and B.1.351 beta, and compared with D614G variant. p values represent the statistic differences as indicated, using paired Student t test with log-transformed variables.

In females, in participants 19-59 years and in individuals without high risk comorbidities the analysis of immunological variables by participants’ subgroups indicated significant increase (p<0.00005) in all variables except for conventional virus neutralization titer (cVNT₅₀) (Supplementary materials Appendix B, Table 2). Compared to placebo, in the vaccine group there was a significant increase in the immune response for all subgroups (data no shown).

There was a good correlation among all variables (coefficients > 0.8) except for cVNT₅₀, this one evaluated in a small number of participants (Supplementary materials Appendix B, Table 3).

Figure 4 shows immunogenicity results in subjects 7-8 months after completing the vaccination schedule. As expected, the specific antibody concentration (median 20.6; 25^th-75^th percentile 6.9; 58.3) decreased significantly (p<0.0001) compared to those after second (24.9; 25^th-75^th percentile 8.2; 85.6) and third dose (121.8; 25^th-75^th percentile 44.5; 343.7) and to CCSP (50.8; 25^th-75^th percentile 23.8; 94.0) (Figure 4A, Supplementary materials Appendix B, Table 4). The proportion of subjects with seroconversion after 7-8 months (73.0%) is similar to that obtained after two doses (74.6%) (Supplementary materials Appendix B, Table 4). Interesting, the mVNT₅₀ GMT (149.6; 95% CI: 122.3; 182.9)) was significantly higher than those after second dose and CCSP (Figure 4B, Supplementary materials Appendix B, Table 4).

• Download figure
• Open in new tab

Figure 4.

Immunogenicity in vaccinated subjects 7-8 months after completing the immunization schedule (two doses SOBERANA 02 + one dose SOBERANA Plus, 28 days apart). A) Anti-RBD IgG concentration expressed in arbitrary units/mL (median, 25^th-75^th percentile). B) Molecular virus neutralization titer mVNT₅₀, highest serum dilution inhibiting 50% of RBD:hACE2 interaction (GMT, 95% CI).

Footnote: Blue dots: response after two doses (on T0, T28) of SOBERANA 02. Green dots: response at T70 or T84 after receiving on T56 the third dose, this one SOBERANA Plus (on T). Brown dots: response after 7-8 months. CCSP (purple): Cuban Convalescent Serum Panel. p value: statistic differences.

Safety analysis

Of the 810 participants, 44.4% presented some AE. In total, 947 AEs of 80 types were reported, 92.6% classified as mild (77.3% consistent with vaccination and 70.7% related to the product under investigation). Eight serious AEs were reported (one —multiform erythema— was consistent with vaccination due to inherent conditions of the subject) (Table 2 and Supplementary materials Appendix B Table 5). The most frequent local solicited AE in both vaccine and placebo groups was pain at injection site (35.5% vs. 8.8%, respectively) followed by swelling (only in vaccine group, 13.0%). General discomfort (4.1% vs. 2.9%, respectively in vaccine and placebo groups) was the most frequent solicited AE at systemic level; other AEs had frequencies < 1% (Table 3). Frequency of unsolicited AEs were 22.5% and 18.6% in vaccine and placebo groups respectively, with headache (5.5%) and hypertension (3.8%) as more recurrent (Supplementary materials Appendix B Tables 7 and 8). One participant in vaccine group died from lung and pancreas neoplasm and pneumonia, classified as serious and severe AEs but no consistent with vaccination. The number of vaccinated subjects reporting AEs decreased after the second and third doses (Supplementary materials Appendix B Figure 1, Table 6).

The likelihood ratio (from Bayes factor) was used as benefit-risk index. We observed a strong evidence for benefit in the vaccine group, (Supplementary materials Appendix B, Figure 2).

API comparison

The frequency of subjects with AEs as well as their characterization was similar in both subgroups vaccinated with two batches of active pharmaceutical ingredient of SOBERANA 02. The confidence intervals for the immunological tests for both batches have a high intersection, suggesting similarity in the immune response (Supplementary materials Appendix B Tables 9, 10 and 11).